Moderate Resting Hypoxaemia In Fibrotic Interstitial Lung Disease

Long-term oxygen therapy (LTOT) is universally accepted as standard care for patients with severe resting hypoxaemia, irrespective of underlying diagnosis, with the aim being to improve patient survival. Chronic obstructive pulmonary disease (COPD) and fibrotic interstitial lung disease (ILD) are the two most common indications for LTOT globally [1–4]. As therapeutic benefits of LTOT have only been established in patients with COPD [5, 6], current prescribing recommendations are based on the study entry criteria used in the pivotal clinical trials of LTOT in COPD [5, 6].\n\nFootnotes \n\nThis manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.\n\nConflict of interest: Dr. Khor reports in-kind clinical trial support from Air Liquide Healthcare, grants and personal fees from Boehringer Ingelheim, and personal fees from Roche, outside the submitted work.\n\nConflict of interest: Dr. Harrison has nothing to disclose.\n\nConflict of interest: Dr. Robinson has nothing to disclose.\n\nConflict of interest: Dr. Goh reports in-kind clinical trial support from Air Liquide Healthcare, grants and personal fees from Boehringer Ingelheim, and personal fees from Roche, outside the submitted work.\n\nConflict of interest: Dr. Glaspole reports personal fees from Boehringer Ingelheim, Roche, and Menarini, outside the submitted work.\n\nConflict of interest: Dr. McDonald reports in-kind clinical trial support from Air Liquide Healthcare, grants from Boehringer Ingelheim, personal fees from GSK and Novartis, and others from Menarini, outside the submitted work.